Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(34 sites)

Argentina

GSK Investigational Site, Almagro

GSK Investigational Site, Buenos Aires

Botswana

GSK Investigational Site, Francistown

Brazil

GSK Investigational Site, Porto Alegre

GSK Investigational Site, Rio de Janeiro

GSK Investigational Site, São Paulo

Eswatini

GSK Investigational Site, Mbabane

Kenya

GSK Investigational Site, Kisumu

Malawi

GSK Investigational Site, Blantyre

GSK Investigational Site, Lilongwe

Peru

GSK Investigational Site, Lima

GSK Investigational Site, Piura

South Africa

GSK Investigational Site, Cape Town

GSK Investigational Site, City of Cape Town

GSK Investigational Site, City of Johannesburg

GSK Investigational Site, Durban

GSK Investigational Site, Isipingo

GSK Investigational Site, Sol Plaatjie

Thailand

GSK Investigational Site, Chiang Mai, Chiang Mai

GSK Investigational Site, Pathum Wan

Uganda

GSK Investigational Site, Entebbe

GSK Investigational Site, Kampala

Zimbabwe

GSK Investigational Site, Chitungwiza

GSK Investigational Site, Harare